Transmedics Group In

US89377M1099 · TMDX (NGM)

0 value funds · 4 CNMV managers

1-year price history

Source: Yahoo Finance

The chart uses daily closes adjusted by the available provider. There may be delays, gaps or differences versus the official source.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

Healthcare · Medical Devices
https://www.transmedics.com

Value funds holding it

Of the value funds we track closely. A different universe and period from "CNMV managers": never added together.

See in Radar Fondos →

CNMV managers

2 → 4 (+2) · net presence change vs. previous period

See context in Radar Gestoras →

Funds (CNMV universe)

2 → 5 (+3) · net presence change vs. previous period

Avg. weight

1.70%

Price

70.78 USD

Sector

Healthcare

Industry

Medical Devices

CNMV data · half-year closed 2025-12-31.

Price for TMDX (NGM), updated 2026-10-18. Source: Yahoo Finance.

Funds holding this company

CNMV period H2 2025. Weight is the sum of every instrument of the company that fund holds (local share, ADR or another class), not just one.

Fund Manager Weight

ATMOS GLOBAL, FI RENTA 4 GESTORA, S.G.I.I.C., S.A. 2.96% CINVEST,FI GESALCALA, S.A., S.G.I.I.C. 2.79% GESTION BOUTIQUE VI, FI ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. 2.13% A&P LIFESCIENCE FUND, FI WELZIA MANAGEMENT, SGIIC, S.A. 0.43% GESTIÓN BOUTIQUE III, FI ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. 0.19%

Company-level moves

Compares H1 2025 with H2 2025, summing every instrument of the company each fund holds. A fund switching instrument within the same company doesn't show up here as an entry or exit — for that instrument-by-instrument detail, see the Instruments section.

New positions: 3 Exits: 0 Increasing exposure: 0 Reducing exposure: 1

+ ATMOS GLOBAL, FI

Enters the position at 2.96% weight.

+ GESTIÓN BOUTIQUE III, FI

Enters the position at 0.19% weight.

+ A&P LIFESCIENCE FUND, FI

Enters the position at 0.43% weight.

Objective ratios

FCF yield

1.4%

Net debt / EBITDA

3.42x

P/E

—

52-week range

60.10 – 156.00 USD

Data as-is, not an interpretation: it does not say whether the price is cheap or expensive, and it is not a buy or sell recommendation.

Updated 2026-09-06. Source: Yahoo Finance.

Disclaimer

This is not financial advice. Weights come from the periodic reports each manager files with the CNMV and lag the real close of the period. Price, description and ratios, when available, come from Yahoo Finance and may not exactly match this ISIN if the company has multiple share classes.